Harrow, Inc. filings document an ophthalmic pharmaceutical business built around branded products and ImprimisRx, including operating results, stockholder communications and Regulation FD presentations tied to its U.S. commercialization strategy. Current reports disclose material events such as product and business updates, executive appointments and compensation arrangements, the completed Melt Pharmaceuticals acquisition, and capital-structure matters involving senior unsecured notes due 2030.
Proxy materials cover shareholder voting matters, board governance and executive compensation. The filing record also includes disclosures on material agreements, risk-related cautionary statements, and clinical or regulatory topics connected to Harrow's ophthalmic product portfolio.
Director Adrienne L. Graves of Harrow received a new equity compensation award on June 20, 2025, as reported in this Form 4 filing. The transaction details include:
- Awarded 7,339 Restricted Stock Units (RSUs) with $0 exercise price
- RSUs will vest fully on the one-year anniversary of the grant date
- Underlying shares cannot be delivered, transferred, or sold until termination of service
This grant appears to be part of the company's director compensation program, representing a standard compensatory award for board service. The filing was submitted by Andrew R. Boll as Attorney in Fact for the director on June 24, 2025, within the required reporting window. Ms. Graves holds these RSUs under direct ownership.
Harrow has filed a Form S-8 registration statement to register securities under its new 2025 Incentive Stock and Awards Plan. The company, an accelerated filer based in Nashville, Tennessee, is registering shares for employee benefit purposes.
Key aspects of the filing include:
- Registration covers the newly adopted 2025 Incentive Stock and Awards Plan
- Filing incorporates by reference the Annual Report for 2024, Q1 2025 Quarterly Report, and recent Current Reports
- Company maintains comprehensive indemnification provisions for directors and officers under Delaware law
- Legal opinion provided by Holland & Knight LLP regarding share legality
- Independent accounting firms Crowe LLP and KMJ Corbin & Company LLP provided consents
The filing includes standard undertakings regarding post-effective amendments and removal of unsold securities. Mark L. Baum, CEO, and Andrew R. Boll have been granted power of attorney for filing amendments.
Key Takeaway: Harrow Inc.’s 2025 Annual Meeting (18-Jun-2025) produced broad shareholder support on every agenda item, reaffirming governance stability without introducing immediate balance-sheet or earnings effects.
A strong quorum of 31.27 million shares (85.2 % of the 36.69 million entitled) was present. All four director nominees—Mark L. Baum, Adrienne L. Graves, Lauren P. Silvernail and Perry J. Sternberg—were re-elected with at least 98.8 % of votes cast, signalling investor confidence in existing leadership.
The new 2025 Incentive Stock and Awards Plan passed with 21.70 million ‘For’ (90.5 % of votes cast, excl. broker non-votes) versus 1.77 million ‘Against’. The plan gives the board fresh equity-compensation capacity, potentially increasing future dilution if fully utilised.
Audit matters were routine: shareholders ratified Crowe LLP for FY-2025 with 31.23 million ‘For’ (99.8 %), removing audit-continuity uncertainty. Advisory votes showed 94.1 % support for executive pay and 82.5 % support for holding a say-on-pay vote every year.
No M&A, financing, or earnings guidance was disclosed. Overall, this 8-K reflects standard corporate-governance maintenance rather than a catalyst for near-term valuation change.